<DOC>
	<DOCNO>NCT00744354</DOCNO>
	<brief_summary>RATIONALE : Vorinostat bortezomib may stop growth cancer cell block enzymes need cell growth . Bortezomib may also stop growth multiple myeloma block blood flow tumor . Drugs use chemotherapy , doxorubicin hydrochloride liposome , work different way stop growth cancer cell , either kill cell stop divide . Giving doxorubicin hydrochloride liposome together vorinostat bortezomib may kill cancer cell . PURPOSE : This phase I trial study side effect best dose vorinostat see well work give together bortezomib doxorubicin hydrochloride liposome treating patient relapse refractory multiple myeloma .</brief_summary>
	<brief_title>Vorinostat , Bortezomib , Doxorubicin Hydrochloride Liposome Treating Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose vorinostat add standard regimen bortezomib pegylated liposomal doxorubicin hydrochloride patient relapse refractory multiple myeloma . - To identify dose-limiting toxicity regimen patient . Secondary - To gain preliminary evidence antitumor activity regimen patient . - To assess degree proteasome inhibition achieve regimen patient . - To evaluate accumulation acetylate alpha-tubulin treatment vorinostat . - To evaluate overall survival , time progression , progression-free survival patient treat regimen . OUTLINE : This multicenter , dose escalation study vorinostat . Patients receive oral vorinostat daily day 1,2 ; 4,5 ; 8 , 9 ; 11 , 12 ; bortezomib IV day 1 , 4 , 8 , 11 , pegylated liposomal doxorubicin hydrochloride IV day 4 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Blood sample collect periodically proteasome inhibition assay acetylate alpha-tubulin study . After completion study treatment , patient follow 1 3 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma Relapsed refractory disease PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 3 month ANC ≥ 1.0 x 10^9/L ( granulocyte growth factor support , e.g. , GCSF GMCSF allow ) Platelet count ≥ 100 x 10^9/L ( erythropoietin allow , platelet RBC transfusion within past 2 week ) Hemoglobin ≥ 8 g/dL ( erythropoietin allow , platelet RBC transfusion within past 2 week ) Creatinine clearance ≥ 30 mL/min AST ALT ≤ 2.5 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment LVEF ≥ 45 % MUGA ECHO Symptomatic neuropathy &lt; grade 2 No known history HIV No active serious infection , medical psychiatric illness would preclude study participation No active hepatitis B C infection No prior concurrent malignancy except adequately treat basal cell squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy , cancer patient diseasefree ≥ 3 year No history hypersensitivity reaction bortezomib component ( boron , mannitol ) , vorinostat , doxorubicin hydrochloride , component PLD No serum potassium ≤ 3.0 serum magnesium ≤ 1.6 correct supplementation exclude Patients must adequate cardiovascular function , define follow : No EKG evidence active , clinically significant conduction system abnormalities No EKG evidence QTc prolongation &gt; grade 2 NOTE : Any EKG abnormality screen document investigator medically significant . PRIOR CONCURRENT THERAPY : No limit number prior treatment regimen At least 30 day since prior therapy recover At least 3 month since prior autologous stem cell transplantation recover Prior allogeneic stem cell bone marrow transplantation allow provide follow criterion meet : More 1 year since transplantation No longer receive immunosuppressive therapy treatment graftversushost disease ( GVHD ) prophylaxis No active GVHD No active , uncontrolled infection No major surgery within past 3 week No prior anthracycline dose &gt; 360 mg/m^2 doxorubicin hydrochloride ( include pegylated liposomal doxorubicin hydrochloride [ PLD ] ) 720 mg/m^2 epirubicin hydrochloride No prior concurrent histone deacetylase inhibitor ( e.g. , valproic acid ) No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF ) course 1 No concurrent investigational anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>